MSInsight

Executive Summary

MSInsight is a French health-tech company specializing in precision oncology diagnostics through advanced genomic analysis and artificial intelligence. Founded in 2019 and based in Paris, the company focuses on detecting microsatellite instability (MSI), a critical biomarker for guiding personalized cancer treatments, particularly in immunotherapy. Its flagship product, MSIcare, is a software tool designed to analyze next-generation sequencing (NGS) data from both solid tumors and liquid biopsies, offering a non-invasive approach to MSI detection. By leveraging AI to enhance accuracy and speed, MSInsight addresses a growing need for reliable MSI testing in clinical settings, where current methods can be inconsistent or require invasive samples. The company operates in the expanding precision oncology market, with potential applications across multiple cancer types. While still in early stages, MSInsight's technology positions it to capture value as MSI testing becomes standard for immunotherapy patient selection.

Upcoming Catalysts (preview)

• Q3 2026CE-IVD Mark Approval for MSIcare70% success
• Q4 2026Publication of Validation Study in Peer-Reviewed Journal80% success
• Q1 2027Strategic Partnership with Major Pharma for Immunotherapy Trial50% success